[Form 4] CRYO CELL INTERNATIONAL INC Insider Trading Activity
Rhea-AI Filing Summary
Cryo-Cell International (CCEL) Chairman and Co-CEO David Portnoy filed a Form 4 reporting open-market purchases of common stock. On 11/20/2025, he acquired 289 shares at $4.00 per share, and on 11/21/2025 he acquired 800 shares at $4.04 and additional shares at $4.09 and $4.10, including purchases held as custodian for his son. Following these transactions, his directly held common stock increased to 847,629 shares, with additional indirect holdings through family accounts and various entities.
The filing also lists several stock option grants over prior years with exercise prices between $4.30 and $12.27, covering amounts such as 280,000 and 50,000 underlying shares, and expirations from 2027 to 2030. Some options vest over time on specified future dates, while one grant vests in full if the company’s share price reaches $25.00 during its seven-year term.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 800 | $4.04 | $3K |
| Grant/Award | Common Stock | 677 | $4.09 | $3K |
| Grant/Award | Common Stock | 406 | $4.09 | $2K |
| Grant/Award | Common Stock | 273 | $4.10 | $1K |
| Grant/Award | Common Stock | 289 | $4.00 | $1K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
FAQ
What insider activity did David Portnoy report for Cryo-Cell International (CCEL)?
David Portnoy reported open-market purchases of Cryo-Cell common stock. On 11/20/2025 he bought 289 shares at $4.00, and on 11/21/2025 he bought additional lots at $4.04, $4.09, and $4.10 per share, including shares for a custodial account for his son.
What is David Portnoy’s role and relationship to Cryo-Cell International (CCEL)?
David Portnoy is listed as a Director, Chairman, Co-CEO, and 10% owner of Cryo-Cell International Inc. This status requires him to report changes in his beneficial ownership of the company’s securities on Form 4.
What stock options in CCEL does David Portnoy hold according to this Form 4?
The filing shows multiple stock option grants with exercise prices such as $7.53, $7.28, $12.27, $4.77, $4.30, $6.47, and $8.08, covering amounts like 26,243, 23,636, 280,000 and 50,000 underlying shares, with expirations between 2027 and 2030.
How do David Portnoy’s CCEL stock options vest?
Vesting terms vary by grant. Some options vest in tranches on specific dates, such as portions vesting on 12/22/2024, 12/22/2025, 1/2/2025, and 1/2/2026. One grant vests immediately if Cryo-Cell’s common stock price reaches $25.00 per share during its seven-year term, while others vest one-third upon issuance and one-third on later stated dates.